NCT06276504View on ClinicalTrials.gov

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
DRUG

Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection

Pembrolizumab administration at D0, M1 and M2

Trial Locations (3)

75013

Hôpital Pitié-Salpêtrière - Médecine Intensive Réanimation, Paris

Hôpital Pitié-Salpêtrière - Service d'hématologie clinique, Paris

Hôpital Pitié-Salpêtrière - Service des Maladies infectieuses et tropicales, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06276504 - Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection | Biotech Hunter | Biotech Hunter